| scholarly article | Q13442814 |
| P50 | author | Amanda Feilding | Q4947737 |
| P2093 | author name string | H Valerie Curran | |
| Celia J A Morgan | |||
| Mark Muetzelfeldt | |||
| Louise A Noronha | |||
| P2860 | cites work | Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials | Q22241828 |
| Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later | Q24606321 | ||
| Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects | Q24613764 | ||
| High-potency cannabis and the risk of psychosis | Q24651025 | ||
| Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance | Q28250818 | ||
| Development of a rational scale to assess the harm of drugs of potential misuse | Q28294714 | ||
| Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis | Q34005713 | ||
| Drug harms in the UK: a multicriteria decision analysis | Q34024516 | ||
| Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population | Q34124581 | ||
| Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. | Q34141036 | ||
| Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up | Q34166349 | ||
| Ketamine use: a review | Q34202404 | ||
| Scheduling of newly emerging drugs: a critical review of decisions over 40 years | Q37949011 | ||
| Drugs as instruments: a new framework for non-addictive psychoactive drug use. | Q39688095 | ||
| Politics and science in classifying the dangers of drugs | Q42841435 | ||
| Harms associated with psychoactive substances: findings of the UK National Drug Survey | Q43235410 | ||
| A web-based survey on mephedrone | Q45421878 | ||
| How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale | Q46094314 | ||
| Improved ranking of drugs on harmfulness can bring sense and order to a failed system | Q46367217 | ||
| Can psychedelics have a role in psychiatry once again? | Q46520984 | ||
| Nutt et al.'s harm scales for drugs--room for improvement but better policy based on science with limitations than no science at all. | Q50788011 | ||
| Drug classification: science, politics, both or neither? | Q51856067 | ||
| Basing drug scheduling decisions on scientific ranking of harmfulness: false promise from false premises. | Q52299353 | ||
| Is there a case for MDMA-assisted psychotherapy in the UK? | Q53203541 | ||
| User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study | Q56069771 | ||
| Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice | Q72305895 | ||
| Sacramental and spiritual use of hallucinogenic drugs | Q82461274 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 497-506 | |
| P577 | publication date | 2013-02-25 | |
| P1433 | published in | Journal of Psychopharmacology | Q6295819 |
| P1476 | title | Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users | |
| P478 | volume | 27 |
| Q36393003 | Adverse psychosocial outcomes associated with drug use among US high school seniors: a comparison of alcohol and marijuana. |
| Q26746137 | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years |
| Q55073777 | Cannabis and Canada's children and youth. |
| Q96811819 | Cocaine use in university students: relationships with demographics, mental health, risky sexual practices, and trait impulsivity |
| Q34460381 | Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach |
| Q43842167 | Differential effects of MDMA and methylphenidate on social cognition. |
| Q58605790 | Does perception of drug-related harm change with age? A cross-sectional online survey of young and older people |
| Q64137325 | Exploring substance use and impaired driving among adults aged 21 years and older in the United States, 2015 |
| Q92574029 | Individuals with Hyperthyroidism are More Susceptible to having a Serious Serotonin Syndrome Following MDMA (Ecstasy) Administration in Rats |
| Q55095986 | Le cannabis et les enfants et adolescents canadiens. |
| Q37542856 | MDMA decreases the effects of simulated social rejection |
| Q58777138 | Marijuana and the lung: hysteria or cause for concern? |
| Q34021975 | Marijuana use and achievement of abstinence from alcohol and other drugs among people with substance dependence: a prospective cohort study. |
| Q47697448 | Recreational 3,4-methylenedioxy-N-methylamphetamine (MDMA) or 'ecstasy' and self-focused compassion: Preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices |
| Q47916065 | Self-Medication of Somatic and Psychiatric Conditions Using Botanical Marijuana. |
| Q47310452 | Social cognition and interaction in chronic users of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). |
| Q36393018 | The moderating effects of perceived emotional benefits on inhalant initiation among American Indian and white youth |
| Q34495787 | The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. |
| Q89620162 | Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials |
Search more.